Alkem Labs Daman facility gets 3 major, few minor observations from Malta Medicines Authority
Mumbai: Alkem Labs has announced that the Malta Medicines Authority has concluded an inspection with three major observations and a few minor observations at the Company’s manufacturing facility located at Daman, India.
The GMP inspection at the said facility was conducted from 05th December, 2025 to 09th December, 2025.
"The said inspection concluded on 09th December, 2025, with no critical observations, three major observations and a few minor observations," the company stated in a BSE filing.
"The Company shall however address the said observations within the stipulated timeframe for closure of the same," Alkem added.
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, Ophthalmology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
Next Story